References:
  1. Conti-Fine BM, Milani M, Kaminski HJ. Myasthenia gravis: past, present, and future. J Clin Invest . 2006;116(11):2843-2854. doi:10.1172/JCI29894
  2. Benamer HT, Bredan A. The epidemiology of myasthenia gravis in Arab countries: a systematic review. Muscle Nerve . 2015;51(1):144-145. doi:10.1002/mus.24350
  3. Sasi S, Yassin MA, Fadul AM. A Case of Acquired von Willebrand Disease Secondary to Myeloproliferative Neoplasm. Case Rep Oncol . 2020;13(2):733-737. Published 2020 Jun 26. doi:10.1159/000507883
  4. Turkina A, Wang J, Mathews V, Saydam G, Jung CW, Al Hashmi HH, Yassin M, Le Clanche S, Miljkovic D, Slader C, Hughes TP. TARGET: a survey of real‐world management of chronic myeloid leukaemia across 33 countries. British Journal of Haematology. 2020 Mar 30
  5. Yassin MA, Taher A, Mathews V, Hou HA, Shamsi T, Tuğlular TF, Xiao Z, Kim SJ, Depei W, Li J, Rippin G. MERGE: a multinational, multicenter observational registry for myeloproliferative neoplasms in Asia, including Middle East, Turkey, and Algeria. Cancer Medicine. 2020 Apr 30.
  6. Al-Dewik N, Ben-Omran T, Zayed H, Trujillano D, Kishore S, Rolfs A, Yassin MA. Clinical exome sequencing unravels new disease-causing mutations in the myeloproliferative neoplasms: a pilot study in patients from the state of Qatar. Gene. 2019 Mar 20;689:34-42.
  7. Dührsen U, Augener W, Zwingers T, Brittinger G. Spectrum and frequency of autoimmune derangements in lymphoproliferative disorders: analysis of 637 cases and comparison with myeloproliferative diseases. Br J Haematol . 1987;67(2):235-239. doi:10.1111/j.1365-2141.1987.tb02333.x
  8. Kumar P, Jain P, Menon H, Purvish P. Chronic myeloid leukemia presenting as paraneoplastic ocular myasthenia gravis. Ann Oncol . 2007;18(4):804-805. doi:10.1093/annonc/mdm010
  9. Sharma N, Dua H, Rosha D. Chronic myeloid leukemia with an unusual paraneoplastic syndrome. J Assoc Physicians India . 2012;60:47-48.
  10. Eivaz-Mohammadi S, Gonzalez-Ibarra F, Hekmatjou H, Mikkilineni R, Patel A, Syed AK. Myasthenia gravis-like syndrome presenting as a component of the paraneoplastic syndrome of lung adenocarcinoma in a nonsmoker. Case Rep Oncol Med . 2014;2014:703828. doi:10.1155/2014/703828
  11. Lengfelder E, Berger U, Hehlmann R. Interferon alpha in the treatment of polycythemia vera. Ann Hematol. 2000 Mar;79(3):103-9. doi: 10.1007/s002770050563. PMID: 10803930.
  12. Bolay H, Karabudak R, Aybay C, Candemir H, Varli K, Imir T, Kansu E. Alpha interferon treatment in myasthenia gravis: effects on natural killer cell activity. J Neuroimmunol. 1998 Mar 1;82(2):109-15. doi: 10.1016/s0165-5728(97)00146-x. PMID: 9585806.
  13. Gurtubay IG, Morales G, Aréchaga O, Gállego J. Development of myasthenia gravis after interferon alpha therapy. Electromyogr Clin Neurophysiol. 1999 Mar;39(2):75-8. PMID: 10207675.
  14. Batocchi AP, Evoli A, Servidei S, Palmisani MT, Apollo F, Tonali P. Myasthenia gravis during interferon alfa therapy. Neurology. 1995 Feb;45(2):382-3. doi: 10.1212/wnl.45.2.382. PMID: 7854543.
Figure Legends:Fig. 1. Ultrasound abdomen of Patient 1 showing massive splenomegaly
Fig. 2. Ultrasound abdomen of Patient 2 showing massive splenomegaly